Sign In
Buy MTSR
$70.50
+0 (+0%)
At Close: Feb 12, 2026
Delaware judge says she will not block Metsera from ending Pfizer deal
04:20pm, Wednesday, 05'th Nov 2025
A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $
Pfizer says it removed some conditions from its Metsera bid
02:19pm, Wednesday, 05'th Nov 2025
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Dela
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
10:07am, Wednesday, 05'th Nov 2025
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
09:20am, Wednesday, 05'th Nov 2025
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera
05:42am, Wednesday, 05'th Nov 2025
Management lowers full-year guidance, warns about competition, launches bid for Metsera.
Novo Nordisk CEO: Confident we will close Metsera deal
05:39am, Wednesday, 05'th Nov 2025
Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company finds itself in a bidding war with Pfizer for U.S. biotech firm.
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
02:45pm, Tuesday, 04'th Nov 2025
Adding more drama to Metsera Inc.'s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.
Why Metsera stock's 20% surge signals a fierce Pfizer-Novo Nordisk bidding war
01:02pm, Tuesday, 04'th Nov 2025
Metsera stock (NASDAQ: MTSR) surged roughly 20% on Tuesday after the obesity-focused biotech announced that Novo Nordisk's revised $10 billion acquisition proposal has been deemed “superior” to Pf
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
12:27pm, Tuesday, 04'th Nov 2025
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company a
Pfizer and Novo Nordisk both raise bids for Metsera
12:18pm, Tuesday, 04'th Nov 2025
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo
11:29am, Tuesday, 04'th Nov 2025
A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hear
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
10:42am, Tuesday, 04'th Nov 2025
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked $8.1 billion proposal.
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
09:58am, Tuesday, 04'th Nov 2025
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
09:40am, Tuesday, 04'th Nov 2025
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nord
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
09:31am, Tuesday, 04'th Nov 2025
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior
